Switzerland-based Oviva, one of Europe’s leading providers of digital, reimbursed care for weight-related and chronic conditions, has closed a €200m (US$234m) Series D financing round – one of the largest Series D rounds in digital health – comprising a mix of primary and secondary capital.
The round is led by Sweden-based Kinnevik, which invested €100m, with participation from Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, and Norrsken VC, alongside continued support from existing investor Sofina.
Kinnevik is now Oviva’s largest shareholder, joining a group of new long-term investors and existing backers, among them Sofina and Temasek.
The round will support rising demand for reimbursed digital healthcare and help expand into chronic indications, including hypertension and type 2 diabetes, to help prevent and manage costly comorbidities. The company will also advance its AI-powered tools to better support patients and clinicians.
“Oviva has demonstrated that digital care can deliver measurable health outcomes at scale. By addressing some of the most pressing and costly conditions, we believe the company is already transforming health economics for the heavily strained European healthcare systems”, said Christian Scherrer, senior investment director at Kinnevik. “We see significant potential to expand this model across conditions and geographies and empower Oviva to provide critical infrastructure that European health systems urgently need.”
Founded in 2014 by Kai Eberhardt and Manuel Baumann, Oviva works closely with public health systems, insurers and clinicians. Its programmes are reimbursed across core markets: Germany, UK, and Switzerland. The company has supported more than one million people in improving their health through evidence-based lifestyle and behavioural interventions.
“This investment allows us to do what we set out to do: make effective care accessible to everyone who needs it,” said CEO Eberhardt. “By intervening earlier and supporting patients continuously over time, we help prevent disease progression, free up clinical capacity, and enable healthcare systems to deliver better outcomes with limited resources.”
In 2021, Oviva raised US$80m in Series C funding in a round co-led by Sofina and Temasek, alongside existing investors AlbionVC, Earlybird, Eight Roads Ventures, F-Prime Capital, MTIP, and several angel investors. In 2020, MTIP led a US$21m Series B. It was joined by Earlybird as a new investor. Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures and Partech all participated. In 2017, it raised US$12m in Series A funding. Eight Roads Ventures invested alongside sister fund, F-Prime Capital Partners, Albion Capital, Partech Ventures and Walking Ventures.
Press release: Kinnevik invests USD 100m in Oviva | Kinnevik